

Drug Information Fulltext

FILE DESCRIPTION

Drug Information Fulltext corresponds to two printed publications: *The American Hospital Formulary Service*, which contains information on 1,000 drugs available commercially in the United States, and *The Handbook on Injectable Drugs*, which covers 217 commercially available and 57 investigational drugs in use in the U.S. Drug Information Fulltext may be searched for information on the stability, chemistry, and pharmaco-kinetics of drugs, as well as on their action, usage, dosage, and administration. The file also covers compatibility and interactions of drugs and cautions for use.

SUBJECT COVERAGE

DIF, through controlled indexing terms and related numerical concept codes, makes it possible to search and display complete monographs, sections of monographs, primary text, additional text, tables, references and/or footnotes. Records for an individual drug include trade names, generic name, manufacturer, CAS[®] (Chemical Abstracts Service) Registry Number, therapeutic classification, and textual information in the following subject areas:

- Cautions
- Chemistry
- Compatibility
- Concentration
- Dosage and Administration
- Drug Interactions
- Laboratory Test Interferences
- Mechanism of Action
- Microbiological Resistance
- pH
- Pharmacokinetics
- Pharmacology
- Preparations
- Stability
- Toxicity
- Uses

Sections and subsections include information further divided on a wide range of topics, including such areas as the following:

- Absorption, Distribution, and Elimination
- Blood Levels
- Container and Package Information
- Dependence and Addiction
- Investigational Use
- Mutagenicity and Carcinogenicity
- Pediatric Cautions
- Pediatric Dosage
- Pregnancy Cautions
- Reconstitution
- Solubility and Dissolution
- Special Instructions
- Storage
- Structure and Activity
- Syringe and Administration Set Compatibilities
- Toxicity Treatment

SOURCES

The monographs from the AHFS (American Hospital Formulary Service) *Drug Information* and the *Handbook On Injectable Drugs*, which are the nucleus of DIF, are written after extensive examination of the literature (references are indicated) and are reviewed by an expert panel. The result is an evaluative monograph discussing the manufacturer's claims and actual clinical experience for each drug.

DIALOG FILE DATA

Inclusive Dates: Current
 Update Frequency: Annual
 File Size: 1,523 records as of September 2002

CONTACT

Drug Information Fulltext is produced by the American Society of Health-System Pharmacists. Questions concerning file content should be directed to:

American Society of Health-System Pharmacists
 Emily Morris
 7272 Wisconsin Avenue
 Bethesda, MD 20814
 Phone: 1-301-664-8647
 Fax: 1-301-664-8857
 E-Mail: pdiso@ashp.org

SAMPLE RECORD

DIALOG(R)File 229:Drug Info. Fulltext
(c) 2002 Ameri.Soc.of Health-Systems Pharm. All rts. reserv.

AH=,/SH 00998967 AHFS NO: 84.06 AHFS CLASS: Anti-inflammatory Agents
 SF= SUBFILE: AHFS Drug Information
 MT=,/NA MONOGRAPH TITLE: Clobetasol Propionate
 GN=,/NA GENERIC NAME: Clobetasol Propionate
 MF= MOLECULAR FORMULA: C25H32ClFO5
 SY=,/TN SYNONYMS: Clobetasol 17-Propionate
 IN= INVESTIGATIONAL NO: CCI 4725; GR 2/925
 /TN,TN=,MN= BRAND NAME/MANUFACTURER: Embeline E/Healthpoint; Temovate E/
 GlaxoSmithKline; Olux/Connetics; Clobevate/Stiefel; Cormax/Oclassen;
 Temovate/GlaxoSmithKline; Cormax Scalp Application/Oclassen; Temovate Scalp
 Application/GlaxoSmithKline
 RN= CAS REGISTRY NO: 25122-46-7
 /SH CHEMISTRY AND STABILITY (CH):
 PRIMARY TEXT:
 /SH Chemistry
 /CH, /TX [3115] Clobetasol propionate is a synthetic fluorinated
 corticosteroid.(1,88) [3135,3145] The drug occurs as a white to
 cream-colored, crystalline powder,(1,2,88) is odorless,(2,88) and has
 solubilities of 2 mcg/mL in water at room temperature(1,2,88) and 10 mg/mL
 in alcohol.(2)
 /SH Stability
 /CH, /TX [3345] Clobetasol propionate cream, ointment, and gel should be stored at
 15-30DGC; the cream should not be refrigerated.(1,87) Clobetasol propionate
 solution should be stored at 4-25DGC; the solution should not be used near
 an open flame.(80) Clobetasol propionate foam should be stored at a
 controlled room temperature between 20-25DGC, and exposure to temperatures
 warmer than 49DGC should be avoided.(88) Because the contents of the foam
 are under pressure, the container should not be punctured, used or stored
 near heat or an open flame, or placed into a fire or incinerator for
 disposal.(88)
 /SH ADDITIONAL TEXT: CHEMISTRY AND STABILITY
 /CH, /TX Stability
 [3900] For further information on chemistry, pharmacology, absorption,
 uses, cautions, and methods of application of clobetasol propionate, see
 the Topical Corticosteroids General Statement 84:06.
 /SH PHARMACOKINETICS (PK):
 /PK, /TX PRIMARY TEXT:
 Absorption
 [3815] Percutaneous penetration of clobetasol propionate varies among
 individuals(5,33-35,41,42,61,66,67,69,70) and can be altered by using
 different vehicles;(1,7,18,22,30,31,41,43,67,69,71,73,88) percutaneous
 penetration can be increased by the use of occlusive
 dressings(1,7,8,18,22,62,69,70,72,88) and by inflammation and/or other
 diseases of the epidermal barrier (e.g., psoriasis,
 eczema).(1,18,62,66,70-73,88)
 [3815] Following topical application of clobetasol propionate to most
 areas of normal skin, only small amounts of the drug appear to reach the
 dermis(66) and subsequently the systemic circulation with the usual
 dosage;(61,66,67) however, systemic absorption may be increased when the
 usual dosage is exceeded(3,7,11,13,46,59,61,64,79) or when the skin is
 inflamed or diseased.(1,18,59,62,66,70,72,73) [3855,3815] Mean peak plasma
 clobetasol propionate concentrations of 0.63 ng/mL occurred in one study 8
 hours after a second 30-g dose (applied 13 hours after an initial dose) of
 clobetasol propionate 0.05% ointment in healthy individuals with normal
 skin; mean peak plasma concentrations of the drug were slightly higher and
 occurred 10 hours after the second dose when the 0.05% cream was
 employed.(67) Mean peak plasma concentrations of approximately 2.3 or 4.6
 ng/mL occurred in another study about 3 hours after a single application of
 a 25-g dose of a 0.05% ointment in patients with psoriasis or eczema,
 respectively.(66)
 /SH Elimination
 /PK, /TX [3835] Following percutaneous penetration of clobetasol propionate, drug
 that is systemically absorbed probably follows the metabolic pathways of
 systemically administered corticosteroids.(1,76,88) (See Pharmacokinetics:
 Elimination, in the Corticosteroids General Statement 68:04.) However,
 systemic metabolism of clobetasol has not been fully characterized or
 quantified.(76) Clobetasol and its metabolites are excreted in bile(1,76)
 and in urine(76) in animals.

SAMPLE RECORD (cont'd)

/SH USES (US):
USES

/US,/TX [3225] Clobetasol propionate shares the actions of other topical corticosteroids and is used for the short-term relief of the inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses, including dermatoses of the scalp.(1,3-29,32,74,78,81-86,88)

/SH CAUTIONS (CA):
PRIMARY TEXT:

/CA,/TX [3605,3645,3525,3575] Clobetasol propionate preparations are some of the most potent topical corticosteroid preparations currently available.(33-45,88) Because of its potency, the drug can suppress the hypothalamic-pituitary-adrenal (HPA) axis following topical application, (3,7,11-13,17-20,26,27,46,55,57,59,61,62,64,88) and HPA-axis suppression has occurred following topical dosages as low as 2 g of the 0.05% ointment or cream (1 mg of clobetasol propionate total) or 7 g of the 0.05% foam (3.5 mg of clobetasol propionate total) or 7 g of the 0.05% foam (3.5 mg of clobetasol propionate total) daily.(1,76,88) Because of the drug's potency and potential for causing adverse systemic effects during topical therapy, the usual dosage should not be exceeded and occlusive dressings (including bandages) should not be applied to areas of clobetasol propionate application.(1) (See Dosage and Administration.)

[3605] Pustules on the scalp, tingling, folliculitis, tightening of the scalp, tenderness, dermatitis, alopecia, and headache may occur in some patients receiving clobetasol propionate solution applied to the scalp.(80) Eye irritation also may occur if clobetasol propionate solution comes in contact with the eye(s); if such contact occurs, the affected eye(s) should be flushed with copious amounts of water.(80-83)

[3645,3225] Like other topical corticosteroids, clobetasol should not be used in the treatment of acne,(1,6,18) rosacea,(1,6,18) or perioral dermatitis,(1) or as monotherapy in the treatment of widespread plaque psoriasis.(1) [3645,3625] The manufacturers state that clobetasol propionate preparations are contraindicated in individuals with known hypersensitivity to the drug, other corticosteroids, or any ingredient in the respective formulation.(1,88)

[3645,3225] If concomitant skin infections develop during clobetasol therapy, appropriate antifungal or antibacterial therapy should be initiated; if the infection does not respond promptly to such therapy, clobetasol should be discontinued until the infection has been controlled adequately.(1,80,87,88)

[3645] The manufacturer of clobetasol propionate foam states that if irritation occurs during treatment, the drug should be discontinued and appropriate therapy instituted.(88)

/SH Geriatric Precautions
/CA,/TX [3645,3255] Clinical studies of clobetasol propionate foam did not include sufficient numbers of patients 65 years of age and older to determine whether geriatric patients respond differently than younger patients.(88) While other clinical experience has not revealed age-related differences in response, drug dosage generally should be titrated carefully in geriatric patients, usually initiating therapy at the low end of the dosage range.(88) The greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease and drug therapy observed in the elderly also should be considered.(88)

/SH Mutagenicity and Carcinogenicity
/CA,/TX [3665,3003] No evidence of clobetasol-induced mutagenesis was seen in various in vitro microbial test systems (e.g., Ames test) with or without metabolic activation.(76) [3665] Long-term studies to determine the carcinogenic potential of topical corticosteroids have not been performed to date.(1,88)

/SH Pregnancy, Fertility, and Lactation
/CA,/TX [3655] The teratogenic potential of topical clobetasol propionate is not known;(88) however, the drug appears to undergo percutaneous absorption, and reproduction studies in mice and rabbits using subcutaneous dosages of the drug up to 1 mg/kg and 10 mcg/kg daily, respectively, have revealed evidence of substantial harm to the fetus (e.g., cleft palate, skeletal immaturity, increased stillbirths and fetal resorptions).(1,76,88) Teratogenic effects of clobetasol were observed at subcutaneous dosages about one-fourth to one-twelfth those of betamethasone in these animals.(76,88) [3655,3003] In addition, although the teratogenic potential of topical clobetasol has not been studied, other potent corticosteroids have been shown to be teratogenic in animals following topical application.(1) [3655,3905] For additional information, see Cautions: Pregnancy, Fertility, and Lactation, in the Topical Corticosteroids General Statement 84:06.

SAMPLE RECORD (cont'd)

/SH
/CH,/TX

ADDITIONAL TEXT: CAUTIONS

Clobetasol propionate shares the toxic potentials of other topical corticosteroids, (1,3,7,11-14,17,19-22,26,27,46-65,78,79) and the usual precautions of corticosteroid therapy should be observed.(1,3,46) (See Cautions in the Topical Corticosteroids General Statement 84:06.)

/SH
/DO,/TX

DOSAGE AND ADMINISTRATION (DO):

PRIMARY TEXT:

[3575,3525] Topical clobetasol propionate cream, ointment, and gel are applied sparingly in thin films and are rubbed gently into the affected area twice daily, preferably in the morning and evening.(1,87) Clobetasol propionate foam and solution are applied to affected areas of the scalp twice daily, in the morning and evening.(80,81,84,88) Clobetasol propionate foam is flammable; therefore, exposure to flames or smoking should be avoided during and immediately after application.(88) When clobetasol propionate foam is applied, the canister containing the drug should be inverted and a small amount (up to a maximum of a golf-ball-sized dollop) of the preparation placed into the cap of the canister, onto a saucer, or other cool surface, or directly on the lesion, taking care to avoid contact with the eyes.(88) The foam should not be dispensed directly to the hands, since the foam will begin to melt immediately upon contact with warm skin.(88) Hair should be moved away from the affected area of the scalp to allow application of the drug onto each affected area.(88) The drug should be massaged gently into the affected scalp until the foam disappears; repeat until the entire affected area has been treated.(88)

Some patients may respond initially to once-daily(66) or intermittent therapy (e.g., twice daily 3 days per week).(29) [3525,3645] Clobetasol therapy should be discontinued and a less potent topical corticosteroid preparation substituted as soon as clinically feasible,(77) but dosage should not exceed 50 g of clobetasol propionate 0.05% cream, foam, or ointment or 50 mL of clobetasol propionate 0.05% lotion (25 mg of the drug total) per week, and duration of a course of clobetasol therapy generally should not exceed 14 days.(1,77,80,88) [3525,3645,3215] Many clinicians indicate that more prolonged clobetasol therapy rarely may be necessary in patients with resistant conditions,(3,5,6,9,10,12-14,16,20,21,23,24,27,29,32,74,75,77) but careful monitoring is essential.(75,77) The risk of adverse systemic corticosteroid effects (e.g., HPA-axis suppression, Cushing's syndrome, hyperglycemia) associated with use of this potent corticosteroid must be carefully considered.(1,88) Intermittent maintenance therapy, such as administration of the drug once-(12) or twice-weekly(20,21) for up to 6 months, has resulted in prolonged periods of remission from corticosteroid-responsive dermatoses in some patients.(12,20,21)

[3575,3645] Clobetasol propionate cream, foam, gel, ointment, or solution should not be used with occlusive dressings and patients should be warned that treated areas of the skin should not be bandaged or otherwise covered or wrapped as to be occlusive.(1,80,87,88)

/SH
/PR,/TX

PREPARATIONS (PR):

PRIMARY TEXT:

Clobetasol Propionate

[3474] Topical

[3434] Cream

[3436] 0.05%*

[1050,3403] Cormax ([3413] with propylene glycol and parabens)

[1080,3403] Oclassen

[1050,3403] Embeline E (with propylene glycol)

[1080,3403] Healthpoint

[1050,3403] Temovate ([3413] with propylene glycol)

[1080,3403] GlaxoSmithKline

[1050,3403] Temovate E ([3413] with propylene glycol)

[1080,3403] GlaxoSmithKline

[3434] Foam

[3436] 0.05%

[1050,3403] Olux (with propylene glycol)

[1080,3403] Connetics

[3434] Gel

[3436] 0.05%*

[1050,3403] Clobevate ([3413] with propylene glycol)

[1080,3403] Stiefel

[1050,3403] Temovate ([3413] with propylene glycol)

[1080,3403] GlaxoSmithKline

[3434] Ointment

[3436] 0.05%*

SAMPLE RECORD (cont'd)

[1050,3403] Cormax ([3413] with propylene glycol)
 [1080,3403] Oclassen
 [1050,3403] Temovate ([3413] with propylene glycol)
 [1080,3403] GlaxoSmithKline
 [3434] Solution
 [3436] 0.05%*
 [1050,3403] Cormax Scalp Application ([3413] with isopropyl alcohol 40%
 w/w)
 [1080,3403] Oclassen
 [1050,3403] Temovate Scalp Application ([3413] with isopropyl alcohol
 39.3%)
 [1080,3403] GlaxoSmithKline

INTRODUCTION

[3115,3205] Clobetasol propionate is a synthetic fluorinated corticosteroid. (1)

/SH

REFERENCES (RF):

/RF, /TX

1. Glaxo Derm. Temovate (clobetasol propionate) cream and ointment prescribing information. Research Triangle Park, NC; 1989 Oct.
2. Reynolds JEF, ed. Martindale: the extra pharmacopoeia. 28th ed. London: The Pharmaceutical Press; 1982:463-4.
3. Allenby CF, Main RA, Marsden RA et al. Effect on adrenal function of topically applied clobetasol propionate (Dermovate). Br Med J. 1975; 4:619-21. (IDIS 60244)
 (...)
84. Lassus A. Local treatment of psoriasis of the scalp with clobetasol propionate in alcoholic solution: a comparison of once and twice a day application. Curr Med Res Opin. 1976; 4:214-7.
85. Zar E. Topical clobetasol propionate in the treatment of scalp psoriasis: a medium term follow-up. Curr Ther Res. 1980; 28:997-1001.
86. Roduner J, Krebs A. [Dermovate scalp application in dermatologic practice: a multi-centre study covering the whole of Switzerland.] (German; translation supplied by Glaxo Dermatology.) Ther Umsch. 1980; 37:589-94.
87. Glaxo Dermatology. Temovate (clobetasol propionate) gel prescribing information. Research Triangle Park, NC; 1994 Jan.
88. Connetics Corporation. Olux foam 0.05% (clobetasol propionate) prescribing information. Palo Alto, CA; 2000 Sep.
 Selected Revisions January 2002, (C) Copyright, June 1986, American Society of Health-System Pharmacists, Inc.

TABLES:

[3403] *available by nonproprietary name

DC=, /DE

DESCRIPTORS: [3115] Chemical description; [3205] Pharmacology; [3225] Therapy; [3215] Unlabeled or investigational use; [3525] Dosage schedule; [3575] Administration route; [3645] Precaution contraindication; [3003] Other drug; [3225] Therapy; [3255] Age effect; [3525] Dosage schedule; [3575] Administration route; [3605] Adverse reaction (side effect); [3625] Sensitivity photosensitivity allergy; [3645] Precaution contraindication; [3655] Fetal toxicity; [3665] Carcinogenicity mutagenicity; [3815] Absorption; [3835] Elimination; [3855] Blood CSF level; [3115] Chemical description; [3135] Physical description; [3145] Solubility; [3345] Storage ; [3403] Preparations; [3413] Other chemical ion ingredient; [3434] Dosage form; [3436] Strength concentration

SEARCH OPTIONS

BASIC INDEX

SEARCH SUFFIX	DISPLAY CODE	FIELD NAME	INDEXING	SELECT EXAMPLES
— /DE	— DE	All Basic Index Fields Descriptor ¹	Word Word & Phrase	S CALCIUM(1W)BLOCK? S DOSAGE(W)SCHEDULE/DE S BLOOD CSF LEVEL/DE
/NA	NA	Generic Name, Monograph Title ⁴	Word & Phrase	S CLOBETASOL(W)PROPIONATE/NA S CLOBETASOL PROPIONATE/NA
/SH	SH	AHFS Drug Classification, Section, and Subsection Heading	Word & Phrase	S ANTI(W)INFLAMMATORY/SH S ANTI-INFLAMMATORY AGENTS/SH
/TN	TN	Trade Name, Synonym ⁵	Word & Phrase	S TEMOVATE/TN S CLOBETASOL 17-PROPIONATE/TN
/TX	TX	Text (from all monograph sections)	Word	S CRYSTALLINE(W)POWDER(F)WHITE/TX
MONOGRAPH and SERIALS RECORDS				
/CA	CA	Cautions	Word	S HPA(W)AXIS(F)SUPPRESS?/CA
/CH	CH	Chemistry and Stability	Word	S FLUORINATED(W)CORTICOSTEROID?/CH
/CI	CI	Compatibility Information ²	Word	S ACIDIC(F)SOLUBILIT?/CI
/CI	TA	Compatibility Tables ²	Word	S DEXTROSE(W)CONCENTRATION/CI
/CT	CT	Concentration ²	Word	S STERILE(W)WATER(F)RECONSTITUT?/CT
/DI	DI	Drug Interactions	Word	S ALCOHOL(F)ANTIHISTAMINE?/DI
/DO	DO	Dosage and Administration	Word	S OCCLUSIVE(W)DRESSING?/DO
/LI	LI	Laboratory Test Interferences	Word	S PREGNANCY(W)TEST?/LI
/MA	MA	Mechanism of Action	Word	S DNA(W)SYNTHESIS(F)INHIBIT?/MA
/OT	OT	Other Information ²	Word	S LOW(W)ARTERIAL(W)PH/OT
/PC	PC	Pharmacology	Word	S CALCIUM(1W)BLOCK?/PC
/PH	PH	pH ²	Word	S 5(W)1/PH
/PK	PK	Pharmacokinetics	Word	S PERCUTANEOUS(W)PENETRATION/PK
/PR	PR	Preparations	Word	S TOPICAL(F)TEMOVATE/PR
/RE	RE	Resistance	Word	S MALIGNANT(W)CELL?/RE
/RF	RF	References	Word	S ALLENBY(W)CF/RF
/SP	SP	Spectrum	Word	S ANTIVIRAL(W)ACTIVIT?/SP
/TO	TO	Chronic Toxicity, Acute Toxicity	Word	S OVERDOS?(F)SEIZURE/TO
/US	US	Uses	Word	S CORTICOSTEROID(F)DERMATOSES/US

¹ Also /DF.² Handbook records only.³ These fields occur infrequently.⁴ Also searchable separately in the Additional Indexes as GN= and MT=⁵ Also searchable in the Additional Indexes as TN=

ADDITIONAL INDEXES

SEARCH PREFIX	DISPLAY CODE	FIELD NAME	INDEXING	SELECT EXAMPLES
AH=	AH	AHFS Classification Number	Phrase	S AH=84.06
—	AN	DIALOG Accession Number		
CN=	CN	Chemical Name ³	Phrase	S CN=10-UNDECENOIC ACID
DC=	—	Descriptor Code	Phrase	S DC=3115
GN=	GN	Generic Name	Word & Phrase	S GN=(GLOBETALOL(W)PROPIONATE) S GN=CLOBETASOL PROPIONATE
IN=	IN	Investigational Drug Number ³	Word & Phrase	S IN=ABBOTTS S IN=ABBOTT-50711
MF=	MF	Molecular Formula ³	Phrase	S MF=C25H32CLF05
MN=	MN	Manufacturer	Word & Phrase	S MN=GLAXO S MN=WARNER-LAMBERT
MT=	MT	Monograph Title	Word & Phrase	S MT=(CLOBESASOL(W)PROPIONATE) S MT=CLOBETASOL PROPIONATE
RN=	RN	CAS(R) Registry Number	Phrase	S RN=25122-46-7
SF=	SF	Subfile	Word & Phrase	S SF=FORMULARY S SF=HANDBOOK OF INJECTABLE DRUGS?
SY=	SY	Synonym ³	Word & Phrase	S SY=(CLOBETASOL(W)PROPIONATE) S SY=CLOBETASOL 17-PROPIONATE
TN=	TN	Tradename/Proprietary Name	Word & Phrase	S TN=TEMOVATE S TN=METAMUCIL SUGAR FREE
UD=	—	Update	Phrase	S UD=9999

Drug Information Fulltext

File 229

SPECIAL FEATURES

For command descriptions, enter HELP LIMIT, HELP SORT, HELP RANK, HELP MAP online.

LIMIT	/FORM -- AHFS Drug Information Records /HANDBOOK -- Handbook on Injectable Drugs Records /NOTABLE -- Records without Tabular Data /TABLE -- Records with Tabular Data	S S2/FORM S S2/HANDBOOK S S4/NOTABLE S S4/TABLE
SORT	AH, GN	SORT S13/ALL/GN PRINT S5/5/1-24/AH/GN
RANK	All phrase- and numeric-indexed fields in the Additional Indexes can be ranked. Other RANK codes include: DE, NA	RANK DE RANK MN S4
MAP	NA, RN, SY	MAP RN TEMP S2

PREDEFINED FORMAT OPTIONS

NO.	DIALOGWEB FORMAT	RECORD CONTENT
1	--	DIALOG Accession Number
2	--	Full Record except Tables
3	Medium	AHFS Class Number and Name, Subfile, Monograph Title, Generic Name, Trade Name, Section Titles, CAS Registry Number
4	--	AHFS Class Number and Name, Subfile, Monograph Title, Generic Name, Text (all)
5	Long	Full Record
6	Free	Subfile, Monograph Title, Generic Name, Section Titles
7	--	AHFS Class Number and Name, Subfile, Monograph Title, Generic Name, Trade Name, Section Titles, CAS Registry Number, Descriptors
8	Short	AHFS Class Number and Name, Subfile, Monograph Title, Descriptors, Subsections
9	Full	Full Record
K	--	KWIC (Key Word In Context) displays a window of text; may be used alone or with other formats

OTHER OUTPUT OPTIONS

For an explanation, enter HELP TYPE, HELP UDF, HELP TAG online.

USER DEFINED FORMATS	Display codes listed in the Search Options tables can be used to customize output.	TYPE S3/NA,SH,TN,RN/1-5
TAG	Output can be displayed with tags identifying each display field.	TYPE S3/3/1-5 TAG
DIRECT RECORD ACCESS	If the accession number of a specific record is known, it can be used to display the record directly.	TYPE 1998816/5 DISPLAY 1998775/MT,TN PRINT 1998999/5

FOR ONLINE HELP:

See HELP FIELDS 229 for searchable fields; HELP FORMAT 229 for output formats; HELP LIMIT 229 for limits; HELP RATES 229 for cost information; HELP SORT 229 for sorts.

